Venus Medtech International

Venus Medtech is a prominent player in transcatheter technologies for structural heart disease therapies. Our comprehensive solutions treat all four heart valves within the human heart (TAVR, TPVR, TMVR, TTVR) in addition to hypertrophic cardiomyopathy, hypertensive renal denervation therapy. Founded in 2009 and headquartered in Hangzhou National High-Tech Industrial Development Zone (Binjiang), the company successfully listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2500.HK) in December 2019. Our journey began with the launch of our first product in 2014, under the New Bioprosthetic Aortic Valve Project in China. We followed this with the introduction of the VenusP-Valve in Europe in 2022. We partner with the top physicians across every continent to understand their challenges and identify opportunities. These insights drive novel breakthrough solutions for a better tomorrow. We invest more than $200M in R&D every year, operate in more than 650 centers worldwide, hold a portfolio of more than 800 patents, and boast a track record of more than real-world implantations. As a global leader in the making, Venus Medtech's strategic focus is and will always remain to pioneer innovative technology and equip physicians with the tools they need to enhance the quality of life for patients worldwide.